The overarching finding from this overview is that there is only sparse clinical trial evidence (since the year 2000) to guide selection of empiric antibiotic therapy in patients with complicated, hospital-acquired, Gram-negative IAIs and UTIs.
Clinical investigations are sparse, and trials such as the one presented by Dixon and colleagues in a recent issue of Critical Care are welcome as they provide insight into the possible clinical use of nebulised heparin in this situation.
Indeed, there is a lack of prospective, controlled trials in this field, and treatment effectiveness is basically inferred from the results of sparse open-label trials, retrospective case series, clinical experience and expert opinions.
The robustness of these conclusions is limited by the lack of trials with low risk of bias, sparse data, heterogeneity among trials, and concern regarding small trial bias.
However, the main results were limited by the lack of trials with low risk of bias, sparse data, heterogeneity among trials, and concern regarding small trial bias.
The robustness of this conclusion is limited by the lack of trials with low risk of bias, sparse data, heterogeneity among trials, and concern regarding small trial bias.
Several trials support the benefit of SCs in patients with chronic ischemic cardiomyopathy (ICMP), although the sample sizes have been small and the number of trials sparse.
Low vitamin D intake and levels have been associated with increased joint symptoms in some observational studies but the findings are mixed and evidence from randomized trials sparse.
However, since data on humans are sparse, randomized controlled trials in humans will be necessary to determine whether these effects have public health implications.
192 different random sparse matrix crystallization trials were established with the truncated construct (FtsZ truncated) and 32 different crystallization hits were observed following 1 week of monitoring.
